Jt Comm J Qual Patient Saf. 2022 Aug;48(8):411-418. doi: 10.1016/j.jcjq.2022.04.004. Epub 2022 Apr 22.
Showcasing compliance with Joint Commission Medication Management (MM) standards during accreditation visits is important, but it is equally vital to maintain a state of continuous survey readiness. This article describes a Pharmacy Quality and Internal Audit Program to promote continuous survey readiness and sustained compliance with MM standards.
A comprehensive MM audit was developed to assess for compliance in all inpatient, ambulatory, and procedural areas that use medications, with each area undergoing the internal auditing process at least twice per calendar year. The audit is performed by an MM subject matter expert from the Department of Pharmacy and incorporates electronic chart review, clinical staff interviews, and observations of area-specific medication practices. Notable findings and recommendations are communicated to area-specific leadership. Institutionwide scorecards are compiled to track performance with MM standards, identify opportunities, and determine future focus areas to improve and sustain compliance.
Results revealed consistent compliance (≥ 90%) with a majority of MM standards. These included hazardous medication management, controlled substances compliance, look-alike/sound-alike drugs, medication storage/security, and labeling of medication syringes. Several areas of opportunity were identified: awareness of high-alert medications and risk-reduction safety strategies, compliance with pill cutter standards, and therapeutic duplication of "as needed" medication orders. Subsequent implementation of corrective actions and mitigation strategies resulted in improved compliance rates from < 50% to ≥ 90% for awareness of high-alert medications and risk-reduction strategies, from < 60% to ≥ 80% for compliance with pill cutter standards, and from < 90% to ≥ 90% for therapeutic duplication of "as needed" orders.
Establishment of a Pharmacy Quality and Internal Audit Program allowed for performance tracking, identification of compliance deficiencies, implementation of focused corrective actions, and promotion of continuous survey readiness with MM standards.
在评审访视中展示对联合委员会药物管理 (MM) 标准的合规性很重要,但保持持续接受评审的准备状态同样至关重要。本文描述了一个药房质量和内部审核计划,以促进持续接受评审的准备状态和持续符合 MM 标准。
制定了一项全面的 MM 审核,以评估所有使用药物的住院、门诊和程序区域的合规性,每个区域至少每 12 个月进行两次内部审核流程。审核由来自药房的 MM 主题专家进行,包括电子病历审查、临床工作人员访谈和特定区域药物实践的观察。将显著发现和建议传达给特定区域的领导层。编制机构范围的记分卡,以跟踪 MM 标准的绩效,确定机会,并确定未来的重点领域,以提高和维持合规性。
结果显示,大多数 MM 标准的合规率一致(≥90%)。这些标准包括危险药物管理、受控物质合规性、相似/相似药物、药物储存/安全性以及药物注射器的标签。确定了几个机会领域:高警示药物的认识和降低风险的安全策略的合规性、遵守切药器标准以及按需药物医嘱的治疗重复。随后实施的纠正措施和缓解策略使高警示药物和降低风险策略的认识、切药器标准的遵守以及按需医嘱的治疗重复的合规率从<50%提高到≥90%,从<60%提高到≥80%,从<90%提高到≥90%。
建立药房质量和内部审核计划允许进行绩效跟踪、确定合规缺陷、实施有针对性的纠正措施,并促进持续符合 MM 标准的持续接受评审的准备状态。